BATON ROUGE, LA--(Marketwired - May 31, 2017) - OncBioMune Pharmaceuticals, Inc. (
As disclosed on March 27, 2017, sales for the first six months since the launch of Bekunis® and Cirkused® (for stress) in Mexico totaled approximately US$330,000, with Bekunis® representing the lion's share of sales. With the strong month of May for Bekunis® alone, OncBioMune is confident that it will meet or exceed its 2017 sales goal for the products in the range of US$750,000 to US$850,000.
With the leading competition to Bekunis® recently exiting the market at a time when brand recognition of OncBioMune's product is quickly growing, management anticipates continued acceleration in sales. In order to facilitate greater market penetration, OncBioMune is interviewing industry veterans with the intention of adding a new Product Manager to the staff in June with the primary directive of creating an even higher impact on direct marketing and adding addition drugstores to the sales channel.
"The launch of Bekunis® has certainly been successful, with positive feedback on our marketing that is translating to sales that have regularly exceeded our expectations," commented Manuel Cosme Odabachian, OncBioMune's General Manager of Global Operations. "We are relentless in our pursuit of bringing more products to market in Mexico, efforts that paid off with the approval from the Mexican Ministry of Health this week for our licensed male fertility product Andfrt® that we believe should add at least US$500,000 in sales during its first full year on the market following launch next quarter. Additionally, we have several other products under dossier elaboration for commercialization later this year and ongoing negotiations with international pharmaceutical companies to bring high-revenue prescription drugs to fill areas of unmet need in Mexico."
Sign up for OncBioMune email alerts at: http://oncbiomune.com/email-alerts/.
About OncBioMune Pharmaceuticals, Inc.
OncBioMune Pharmaceuticals is a clinical-stage biopharmaceutical company engaged in the development of novel cancer immunotherapy products, with a proprietary Vaccine Technology that is designed to stimulate the immune system to attack its own cancer while not hurting the patient. Our lead product, ProscaVax™ is scheduled to commence a Phase 2 clinical study in 2016. OncBioMune also has a portfolio of targeted therapies, some of which are biosimilars to blockbuster drugs. OncBioMune is headquartered in Baton Rouge, LA.
This press release does not constitute an offer to sell or a solicitation of an offer to buy the securities in this offering, nor there be any sale of these securities in any jurisdiction in which such offer solicitation or sale are unlawful prior to registration or qualification under securities laws of any such jurisdiction.
This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 that involve risks, uncertainties and assumptions that could cause OncBioMune Pharmaceuticals' actual results and experience to differ materially from anticipated results and expectations expressed in these forward looking statements. OncBioMune Pharmaceuticals has in some cases identified forward-looking statements by using words such as "anticipates," "believes," "hopes," "estimates," "looks," "expects," "plans," "intends," "goal," "potential," "may," "suggest," and similar expressions. Among other factors that could cause actual results to differ materially from those expressed in forward-looking statements are OncBioMune Pharmaceuticals' need for, and the availability of, substantial capital in the future to fund its operations and research and development; the fact that OncBioMune Pharmaceutical's vaccines and therapeutics may not successfully complete pre-clinical or clinical testing, or be granted regulatory approval to be sold and marketed in the United States or elsewhere. A more complete description of these risk factors is included in OncBioMune Pharmaceutical's filings with the Securities and Exchange Commission. You should not place undue reliance on any forward-looking statements. OncBioMune Pharmaceuticals undertakes no obligation to release publicly the results of any revisions to any such forward-looking statements that may be made to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events, except as required by applicable law or regulation.
OncBioMune Pharmaceuticals, Inc.
President and Chief Financial Officer